The global gamma knife market size was valued at USD 171.5 million in 2016. Growing prevalence of cancer, brain tumors, & neurological diseases, as well as increasing adoption of gamma knife instruments in surgical centers owing to rising preference for minimally invasive surgeries, are few factors anticipated to boost the market. Moreover, technological upgradation and advancements are also expected to drive the market.
There is a rapid surge in the global incidence of neurological diseases such as brain tumor and epilepsy. According to data published by American Brain Tumor Association (ABTA) in 2017, nearly 7,00,000 people suffer from brain tumor in the U.S., and nearly 80,000 new primary brain tumor cases are expected to be diagnosed every year. Primarily, there are two types of brain tumors: nonmalignant and malignant. Cancer is the second largest cause of death globally, accounting for approximately 8.8 million deaths worldwide in 2015. According to WHO estimates, cancer incidence is expected to rise by 70% over the next two decades.
According to ABTA data, brain & CNS tumors are the third most common type of cancer responsible for the death of population below 40 years of age. Growing usage of gamma knife therapy in neurological treatment owing to its advantages over conventional surgeries is likely to boost the market. Since it is a non-invasive procedure, it provides better safety, causes less damage to surrounding tissues, and offers micro precision while treating the target cells in the brain.
Rising adoption of these instruments in surgery centers owing to rising prevalence of neurological diseases and increasing preference for minimally invasive techniques is also expected to drive the market. Rapidly increasing demand for recently developed Leksell Gamma Knife Icon and increased requirement for upgradation of this technology are also some factors depicting the surging demand for these devices. For example, in 2015, previous gamma knife models U, B, C, 4C, and Perfexion were upgraded to Leksell Gamma Knife Icon by Elekta Instrument, AB. Thus, ongoing evolution in technology is one of the key factors that can be attributed to its high adoption. Adoption of integrated imaging & software, improved workflow, and increase in clinical applications has also led to high usage of these devices in surgical centers.
On the basis of indications, the gamma knife market is segmented into malignant tumors, benign tumors, vascular disorders, functional disorders, and ocular diseases. In 2016, malignant tumors accounted for maximum revenue share. Gamma knife therapy is used as adjunctive therapy for primary malignant brain tumors. Fractionated external beam radiation therapy is usually preferred over conventional surgical treatment alternatives.
Moreover, rising prevalence of primary brain tumors is also expected to boost demand over the forecast period. In addition, associated advantages of gamma knife therapy over other treatment alternatives, such as improved accuracy, precision, and treatment safety, are anticipated to boost its demand in surgical centers. Unlike other invasive surgical procedures, it requires no incision, and this is also expected to increase demand.
The ocular disease segment is expected to grow at a lucrative rate of approximately 12.1% over the forecast period. Gamma knife therapy is used for various ocular indications, such as uveal melanoma, advanced glaucoma, eye metastases, age-related macular degeneration, angioreticuloma, vegetative pain, and pseudotumor cerebri. It reduces intraocular pressure and latency of this treatment is low as compared to other treatments. Thus, extended applications of this therapy to treat a wide range of ocular indications are expected to boost demand for the same.
Asia Pacific dominated the overall market in terms of revenue in 2016 with a share of 39.6%. High incidence of brain tumor, rising awareness amongst healthcare professionals regarding noninvasive treatment alternatives such as stereotactic surgeries, high adoption of these instruments in surgery centers, and improving healthcare infrastructure are the key factors responsible for dominance of the region.
In 2016, Japan held the largest revenue share in this region. Japan is considered as the second-largest market in terms of volume. Key factors responsible for its dominance are increasing disease burden, rising prevalence of cancers & brain tumors, and growing adoption of gamma knife instruments in surgery centers. For instance, in October 2016, Elekta’s Leksell Gamma Knife Icon was used for the first time to treat a patient with brain metastases in Japan.
Moreover, rapidly developing economies, improvements in healthcare facilities, and rising geriatric population are some of the factors owing to which Asia Pacific is expected to emerge as the fastest-growing region with a growth rate of 4.1% during the forecast period. In June 2015, Samsung Medical Center acquired the first Gamma Knife Icon system in Asia. Thus, growing adoption of high-cost technologically advanced products in this region is one of the key factors that can be attributed to its largest share and fastest growth over the forecast period.
Gamma Knife is a patent-protected trademark of Elekta AB, because of which the company has a monopoly in the market. With investments in R&D, the company is striving to launch new technologically advanced gamma knives to become a leader in innovation.
Report Attribute |
Details |
Market size value in 2020 |
USD 202.7 million |
Revenue forecast in 2025 |
USD 239.2 million |
Growth Rate |
CAGR of 3.7% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2015 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD thousand and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Indications, region |
Regional scope |
North America; Europe; Asia Pacific; Central & South America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; UK; China; India; Brazil; Mexico; South Africa |
Key companies profiled |
Elekta AB; Varian Medical Systems; Cyber Medical Corporation; ET Medical Group; GE Healthcare; Masep Infini Global Inc.; Huiheng Medical, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the gamma knife market on the basis of indications and region:
Indications Outlook (Revenue, USD Thousand, 2014 - 2025)
Malignant tumors
Benign tumors
Vascular disorders
Functional disorders
Ocular diseases
Regional Outlook (Revenue, USD Thousand, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
China
Japan
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
b. The global gamma knife market size was estimated at USD 195.7 million in 2019 and is expected to reach USD 202.7 million in 2020.
b. The global gamma knife market is expected to grow at a compound annual growth rate of 3.7% from 2017 to 2025 to reach USD 243.1 million by 2025.
b. Asia Pacific dominated the gamma knife market with a share of 40.1% in 2019. This is attributable to a high incidence of brain tumors, rising awareness amongst healthcare professionals regarding noninvasive treatment alternatives.
b. Some key players operating in the gamma knife market include Elekta AB, Varian Medical Systems, Cyber Medical Corporation, ET Medical Group, GE Healthcare, Masep Infini Global Inc., and Huiheng Medical, Inc.
b. Key factors that are driving the market growth include the rapid surge in the global incidence of neurological diseases such as brain tumor and epilepsy, rising adoption of the instruments in surgical centers, and product launch.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.